menu search

Biocryst reports third quarter 2023 financial results and provides business update

– Q3 2023 orladeyo net revenue of $85.7 million (+29.8 percent y-o-y) — – Company expects to achi...

November 2, 2023, 11:00 am

Biocryst pharmaceuticals rallies on quebec reimbursement for orladeyo angioedema treatment

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé...

September 18, 2023, 10:53 am

Biocryst selects er-kim pharmaceuticals as commercial partner for orladeyo® (berotralstat) in turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...

July 19, 2023, 11:00 am

Biocryst to present new orladeyo® (berotralstat) data at 2023 european academy of allergy and clinical immunology congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will prese...

May 31, 2023, 7:02 am

Why biocryst pharmaceuticals stock is soaring today

BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its ...

May 3, 2023, 1:44 pm

Biocryst is not currently uncovering the full value of orladeyo

BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ...

February 22, 2023, 9:00 am

Pharmaceutical stock sinks on sales forecast

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock is sinking today, down 11.6% at $10.45 at last glance, after the company's sales forecast for its ski...

January 9, 2023, 3:10 pm

Biocryst pharmaceuticals: more aggressive growth for orladeyo

As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' orladeyo is enjoying strong sale...

December 20, 2022, 4:47 pm

Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...

February 9, 2022, 4:25 pm

Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...

February 9, 2022, 4:25 pm

Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?

By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...

February 9, 2022, 4:25 pm

Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals

Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...

February 7, 2022, 11:56 am

Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals

Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...

February 7, 2022, 11:56 am

Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals

Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...

February 7, 2022, 11:56 am

Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...

February 1, 2022, 9:25 am

Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...

February 1, 2022, 9:25 am

Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...

February 1, 2022, 9:25 am


Search within

Pages Search Results: